Literature DB >> 7782117

Pharmacokinetics of macrolides. Comparison of plasma, tissue and free concentrations with special reference to roxithromycin.

O G Nilsen1.   

Abstract

When macrolide antibiotics are administered according to the standard therapeutic regimens, the highest plasma concentrations of total drug, both during the first dosage interval and at steady state, are obtained with roxithromycin, followed by clarithromycin and azithromycin. The corresponding free plasma concentrations, calculated from published data on plasma protein binding for the three macrolides, are of the same order of magnitude and the highest values are again those of roxithromycin. With the use of improved analytical methodology, a stable and prolonged total elimination half-life of roxithromycin of about 19 h was demonstrated at steady state in healthy adults with a 300 mg once daily dosage regimen. Intra-group subject variations (adults, children, the elderly etc.) were smaller than anticipated. Roxithromycin is found in high and similar concentrations both in plasma and tissue, demonstrating a balanced pharmacokinetic behaviour.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7782117     DOI: 10.1007/bf02464952

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   3.553


  7 in total

1.  High-performance liquid chromatographic assay with electrochemical detection for azithromycin in serum and tissues.

Authors:  R M Shepard; G S Duthu; R A Ferraina; M A Mullins
Journal:  J Chromatogr       Date:  1991-04-19

Review 2.  The pharmacokinetics of clarithromycin and its 14-OH metabolite.

Authors:  P G Davey
Journal:  J Hosp Infect       Date:  1991-09       Impact factor: 3.926

3.  Selection of dose regimens of azithromycin .

Authors:  G Foulds; R B Johnson
Journal:  J Antimicrob Chemother       Date:  1993-06       Impact factor: 5.790

4.  The pharmacokinetics of azithromycin in human serum and tissues.

Authors:  G Foulds; R M Shepard; R B Johnson
Journal:  J Antimicrob Chemother       Date:  1990-01       Impact factor: 5.790

5.  Comparison of the pharmacokinetics of three-day and five-day regimens of azithromycin in plasma and urine.

Authors:  A Wildfeuer; H Laufen; M Leitold; T Zimmermann
Journal:  J Antimicrob Chemother       Date:  1993-06       Impact factor: 5.790

6.  Macrolide pharmacokinetics and dose scheduling of roxithromycin.

Authors:  O G Nilsen; T Aamo; K Zahlsen; P Svarva
Journal:  Diagn Microbiol Infect Dis       Date:  1992 May-Jun       Impact factor: 2.803

Review 7.  Clarithromycin, a unique macrolide. A pharmacokinetic, microbiological, and clinical overview.

Authors:  D J Hardy; D R Guay; R N Jones
Journal:  Diagn Microbiol Infect Dis       Date:  1992-01       Impact factor: 2.803

  7 in total
  5 in total

Review 1.  Pharmacokinetic considerations in the eradication of Helicobacter pylori.

Authors:  U Klotz
Journal:  Clin Pharmacokinet       Date:  2000-03       Impact factor: 6.447

2.  Antimicrobial and immunologic activities of clarithromycin in a murine model of Mycoplasma pneumoniae-induced pneumonia.

Authors:  Robert D Hardy; Ana Maria Rios; Susana Chavez-Bueno; Hasan S Jafri; Jeanine Hatfield; Beverly B Rogers; George H McCracken; Octavio Ramilo
Journal:  Antimicrob Agents Chemother       Date:  2003-05       Impact factor: 5.191

3.  Population-based meta-analysis of roxithromycin pharmacokinetics: dosing implications of saturable absorption and protein binding.

Authors:  Michael J Dolton; David Z D'Argenio
Journal:  J Antimicrob Chemother       Date:  2017-04-01       Impact factor: 5.790

Review 4.  Choosing the right macrolide antibiotic. A guide to selection.

Authors:  L Charles; J Segreti
Journal:  Drugs       Date:  1997-03       Impact factor: 9.546

Review 5.  Ketolides--the modern relatives of macrolides : the pharmacokinetic perspective.

Authors:  Markus Zeitlinger; Claudia Christina Wagner; Birgit Heinisch
Journal:  Clin Pharmacokinet       Date:  2009       Impact factor: 6.447

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.